Interpretation of the global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

CHEN Maoshan ,  LV Qing

Department of Breast Surgery, West China Hospital, Sichuan University, Chengdu, 610041, P. R. China;

Corresponding author：

LV Qing, Email: lqlq1963@163.com

Keywords：

Breast cancer; morbidity; death; risk factor; prevention; guideline interpretation

DOI：

10.7507/1007-4848.202112063

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Recently, the National Cancer Center analyzed the disease burden and epidemiological trend of breast cancer based on the global population registration data, providing important reference for the prevention and control of breast cancer and health decision-making. Based on the current situation of prevention and control of breast cancer in China, this paper briefly interpreted the key points of the disease burden and trend of breast cancer.

Citation： CHEN Maoshan, LV Qing. Interpretation of the global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2022, 29(4): 401-406. doi: 10.7507/1007-4848.202112063 Copy

1.	Bray F, Laversanne M, Weiderpass E, et al. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer, 2021, 127(16): 3029-3030.
2.	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
3.	Lei S, Zheng R, Zhang S, et al. Global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020. Cancer Commun (Lond), 2021, 41(11): 1183-1194.
4.	邹小农, 贾漫漫, 王鑫, 等. 《2020全球癌症报告》要点解读. 中国胸心血管外科临床杂志, 2021, 28(1): 11-18.
5.	United Nations Development Program. Human Development Report 2018: Human Development for Everyone. New York, NY: United Nations Development Program, 2018. 22-33.
6.	Soerjomataram I, Bray F. Planning for tomorrow: Global cancer incidence and the role of prevention 2020-2070. Nat Rev Clin Oncol, 2021, 18(10): 663-672.
7.	Lawson MB, Lee CI, Hippe DS, et al. Receipt of screening mammography by insured women diagnosed with breast cancer and impact on outcomes. J Natl Compr Canc Netw, 2021, Online ahead of print.
8.	Duffy SW, Vulkan D, Cuckle H, et al. Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): Final results of a randomised, controlled trial. Lancet Oncol, 2020, 21(9): 1165-1172.
9.	Harkness EF, Astley SM, Evans DG. Risk-based breast cancer screening strategies in women. Best Pract Res Clin Obstet Gynaecol, 2020, 65: 3-17.
10.	Kresovich JK, Xu Z, O'Brien KM, et al. Methylation-based biological age and breast cancer risk. J Natl Cancer Inst, 2019, 111(10): 1051-1058.
11.	Pfeiffer RM, Webb-Vargas Y, Wheeler W, et al. Proportion of U. S. trends in breast cancer incidence attributable to long-term changes in risk factor distributions. Cancer Epidemiol Biomarkers Prev, 2018, 27(10): 1214-1222.
12.	Nguyen TL, Li S, Dite GS, et al. Interval breast cancer risk associations with breast density, family history and breast tissue aging. Int J Cancer, 2020, 147(2): 375-382.
13.	Kim YY, Kang HJ, Ha S, et al. Effects of living in the same region as one’s workplace on the total fertility rate of working women in Korea. Epidemiol Health, 2019, 41: e2019043.
14.	Zhang Q, Liu LY, Wang F, et al. The changes in female physical and childbearing characteristics in China and potential association with risk of breast cancer. BMC Public Health, 2012, 12: 368.
15.	Gray JM, Rasanayagam S, Engel C, et al. State of the evidence 2017: An update on the connection between breast cancer and the environment. Environ Health, 2017, 16(1): 94.
16.	Rudel RA, Fenton SE, Ackerman JM, et al. Environmental exposures and mammary gland development: State of the science, public health implications, and research recommendations. Environ Health Perspect, 2011, 119(8): 1053-1061.
17.	Teitelbaum SL, Belpoggi F, Reinlib L. Advancing research on endocrine disrupting chemicals in breast cancer: Expert panel recommendations. Reprod Toxicol, 2015, 54: 141-147.
18.	Daly MB, Pal T, Berry MP, et al. Genetic/familial high-risk assessment: Breast, ovarian, and pancreatic, version 2. 2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2021, 19(1): 77-102.
19.	Bevers TB, Helvie M, Bonaccio E, et al. Breast cancer screening and diagnosis, version 3. 2018, NCCN clinical pcractice guidelines in oncology. J Natl Compr Canc Netw, 2018, 16(11): 1362-1389.
20.	Owens DK, Davidson KW, Krist AH, et al. Risk assessment, genetic vounseling, and henetic testing for BRCA-related cancer: US preventive services Task force recommendation statement. JAMA, 2019, 322(7): 652-665.
21.	Shieh Y, Tice JA. Medications for primary prevention of breast cancer. JAMA, 2020, 324(3): 291-292.
22.	Yang Y, Pan L, Shao Z. Trend and survival benefit of contralateral prophylactic mastectomy among men with stage Ⅰ-Ⅲ unilateral breast cancer in the USA, 1998-2016. Breast Cancer Res Treat, 2021, 190(3): 503-515.
23.	Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst, 2001, 93(21): 1633-1637.
24.	Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the women's health initiative randomized controlled trial. JAMA, 2002, 288(3): 321-33.
25.	Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med, 2007, 356(16): 1670-1674.
26.	Coombs NJ, Cronin KA, Taylor RJ, et al. The impact of changes in hormone therapy on breast cancer incidence in the US population. Cancer Causes Control, 2010, 21(1): 83-90.
27.	Parkin DM. Is the recent fall in incidence of post-menopausal breast cancer in UK related to changes in use of hormone replacement therapy? Eur J Cancer, 2009, 45(9): 1649-1653.
28.	Liu LY, Wang YJ, Wang F, et al. Factors associated with insufficient awareness of breast cancer among women in Northern and Eastern China: A case-control study. BMJ Open, 2018, 8(2): e018523.
29.	陈万青, 李霓, 石菊芳, 等. 中国城市癌症早诊早治项目进展. 中国肿瘤, 2019, 28(1): 23-25.
30.	黄静, 杨湘红, 刘爱, 等. 农村地区妇女“两癌筛查”项目实施中的问题与对策. 中国全科医学, 2020, 23(13): 1680-1686.
31.	赫捷, 陈万青, 李霓, 等. 中国女性乳腺癌筛查与早诊早治指南(2021, 北京). 中国肿瘤, 2021, 30(3): 161-191.
32.	Zhao ZZ. Reexamining China’s fertility puzzle: Data collection and quality over the last two decades. Popul Dev Rev, 2006, 32(2): 293-321.
33.	Kobayashi S, Sugiura H, Ando Y, et al. Reproductive history and breast cancer risk. Breast Cancer, 2012, 19(4): 302-308.
34.	Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China. Lancet Oncol, 2014, 15(7): e279-e289.
35.	Lei S, Zheng R, Zhang S, et al. Breast cancer incidence and mortality in women in China: Temporal trends and projections to 2030. Cancer Biol Med, 2021, 18(3): 900-909.
36.	Loibl S, Poortmans P, Morrow M, et al. Breast cancer. Lancet, 2021, 397(10286): 1750-1769.
37.	Chen C, Sun S, Yuan JP, et al. Characteristics of breast cancer in Central China, literature review and comparison with USA. Breast, 2016, 30: 208-213.
38.	莫淼, 袁晶, 周昌明, 等. 以大型单中心的医院登记为基础的3.5万例乳腺癌患者长期生存报告 . 中国癌症杂志, 2020, 30(2): 90-97.
39.	中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2021年版). 中国癌症杂志, 2021, 8(31): 770-856.
40.	郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析. 中华肿瘤杂志, 2019, 41(1): 19-28.
41.	曹毛毛, 陈万青. 中国恶性肿瘤流行情况及防控现状. 中国肿瘤临床, 2019, 46(3): 145-149.
42.	Autier P, Boniol M, La Vecchia C, et al. Disparities in breast cancer mortality trends between 30 European countries: Retrospective trend analysis of WHO mortality database. BMJ, 2010, 341: c3620.
43.	Michael G, Vinod R. Epidemiology, screening and diagnosis of breast cancer in the Asia–Pacific region: Current perspectives and important considerations. Asia-Pac J Clin Oncol, 2008, 4(s3): S5-S13.
44.	Song QK, Li J, Huang R, et al. Age of diagnosis of breast cancer in China: Almost 10 years earlier than in the United States and the European Union. Asian Pac J Cancer Prev, 2014, 15(22): 10021-10025.
45.	Yu ZG, Jia CX, Liu LY, et al. The prevalence and correlates of breast cancer among women in Eastern China. PLoS One, 2012, 7(6): e37784.
46.	Mizukoshi MM, Hossian SZ, Poulos A. Comparative analysis of breast cancer incidence rates between australia and Japan: Screening target implications. Asian Pac J Cancer Prev, 2020, 21(7): 2123-2129.
47.	Sechopoulos I, Mann RM. Stand-alone artificial intelligence - The future of breast cancer screening? Breast, 2020, 49: 254-260.
48.	瞿亚军, 吕青. 我国乳腺癌预防若干问题的思考. 中国普外基础与临床杂志, 2020, 27(11): 1334-1339.
49.	吕青, 瞿亚军. 乳腺良性疾病与乳腺癌风险. 中国普外基础与临床杂志, 2020, 27(11): 1329-1333.

1. Bray F, Laversanne M, Weiderpass E, et al. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer, 2021, 127(16): 3029-3030.
2. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
3. Lei S, Zheng R, Zhang S, et al. Global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020. Cancer Commun (Lond), 2021, 41(11): 1183-1194.
4. 邹小农, 贾漫漫, 王鑫, 等. 《2020全球癌症报告》要点解读. 中国胸心血管外科临床杂志, 2021, 28(1): 11-18.
5. United Nations Development Program. Human Development Report 2018: Human Development for Everyone. New York, NY: United Nations Development Program, 2018. 22-33.
6. Soerjomataram I, Bray F. Planning for tomorrow: Global cancer incidence and the role of prevention 2020-2070. Nat Rev Clin Oncol, 2021, 18(10): 663-672.
7. Lawson MB, Lee CI, Hippe DS, et al. Receipt of screening mammography by insured women diagnosed with breast cancer and impact on outcomes. J Natl Compr Canc Netw, 2021, Online ahead of print.
8. Duffy SW, Vulkan D, Cuckle H, et al. Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): Final results of a randomised, controlled trial. Lancet Oncol, 2020, 21(9): 1165-1172.
9. Harkness EF, Astley SM, Evans DG. Risk-based breast cancer screening strategies in women. Best Pract Res Clin Obstet Gynaecol, 2020, 65: 3-17.
10. Kresovich JK, Xu Z, O'Brien KM, et al. Methylation-based biological age and breast cancer risk. J Natl Cancer Inst, 2019, 111(10): 1051-1058.
11. Pfeiffer RM, Webb-Vargas Y, Wheeler W, et al. Proportion of U. S. trends in breast cancer incidence attributable to long-term changes in risk factor distributions. Cancer Epidemiol Biomarkers Prev, 2018, 27(10): 1214-1222.
12. Nguyen TL, Li S, Dite GS, et al. Interval breast cancer risk associations with breast density, family history and breast tissue aging. Int J Cancer, 2020, 147(2): 375-382.
13. Kim YY, Kang HJ, Ha S, et al. Effects of living in the same region as one’s workplace on the total fertility rate of working women in Korea. Epidemiol Health, 2019, 41: e2019043.
14. Zhang Q, Liu LY, Wang F, et al. The changes in female physical and childbearing characteristics in China and potential association with risk of breast cancer. BMC Public Health, 2012, 12: 368.
15. Gray JM, Rasanayagam S, Engel C, et al. State of the evidence 2017: An update on the connection between breast cancer and the environment. Environ Health, 2017, 16(1): 94.
16. Rudel RA, Fenton SE, Ackerman JM, et al. Environmental exposures and mammary gland development: State of the science, public health implications, and research recommendations. Environ Health Perspect, 2011, 119(8): 1053-1061.
17. Teitelbaum SL, Belpoggi F, Reinlib L. Advancing research on endocrine disrupting chemicals in breast cancer: Expert panel recommendations. Reprod Toxicol, 2015, 54: 141-147.
18. Daly MB, Pal T, Berry MP, et al. Genetic/familial high-risk assessment: Breast, ovarian, and pancreatic, version 2. 2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2021, 19(1): 77-102.
19. Bevers TB, Helvie M, Bonaccio E, et al. Breast cancer screening and diagnosis, version 3. 2018, NCCN clinical pcractice guidelines in oncology. J Natl Compr Canc Netw, 2018, 16(11): 1362-1389.
20. Owens DK, Davidson KW, Krist AH, et al. Risk assessment, genetic vounseling, and henetic testing for BRCA-related cancer: US preventive services Task force recommendation statement. JAMA, 2019, 322(7): 652-665.
21. Shieh Y, Tice JA. Medications for primary prevention of breast cancer. JAMA, 2020, 324(3): 291-292.
22. Yang Y, Pan L, Shao Z. Trend and survival benefit of contralateral prophylactic mastectomy among men with stage Ⅰ-Ⅲ unilateral breast cancer in the USA, 1998-2016. Breast Cancer Res Treat, 2021, 190(3): 503-515.
23. Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst, 2001, 93(21): 1633-1637.
24. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the women's health initiative randomized controlled trial. JAMA, 2002, 288(3): 321-33.
25. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med, 2007, 356(16): 1670-1674.
26. Coombs NJ, Cronin KA, Taylor RJ, et al. The impact of changes in hormone therapy on breast cancer incidence in the US population. Cancer Causes Control, 2010, 21(1): 83-90.
27. Parkin DM. Is the recent fall in incidence of post-menopausal breast cancer in UK related to changes in use of hormone replacement therapy? Eur J Cancer, 2009, 45(9): 1649-1653.
28. Liu LY, Wang YJ, Wang F, et al. Factors associated with insufficient awareness of breast cancer among women in Northern and Eastern China: A case-control study. BMJ Open, 2018, 8(2): e018523.
29. 陈万青, 李霓, 石菊芳, 等. 中国城市癌症早诊早治项目进展. 中国肿瘤, 2019, 28(1): 23-25.
30. 黄静, 杨湘红, 刘爱, 等. 农村地区妇女“两癌筛查”项目实施中的问题与对策. 中国全科医学, 2020, 23(13): 1680-1686.
31. 赫捷, 陈万青, 李霓, 等. 中国女性乳腺癌筛查与早诊早治指南(2021, 北京). 中国肿瘤, 2021, 30(3): 161-191.
32. Zhao ZZ. Reexamining China’s fertility puzzle: Data collection and quality over the last two decades. Popul Dev Rev, 2006, 32(2): 293-321.
33. Kobayashi S, Sugiura H, Ando Y, et al. Reproductive history and breast cancer risk. Breast Cancer, 2012, 19(4): 302-308.
34. Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China. Lancet Oncol, 2014, 15(7): e279-e289.
35. Lei S, Zheng R, Zhang S, et al. Breast cancer incidence and mortality in women in China: Temporal trends and projections to 2030. Cancer Biol Med, 2021, 18(3): 900-909.
36. Loibl S, Poortmans P, Morrow M, et al. Breast cancer. Lancet, 2021, 397(10286): 1750-1769.
37. Chen C, Sun S, Yuan JP, et al. Characteristics of breast cancer in Central China, literature review and comparison with USA. Breast, 2016, 30: 208-213.
38. 莫淼, 袁晶, 周昌明, 等. 以大型单中心的医院登记为基础的3.5万例乳腺癌患者长期生存报告 . 中国癌症杂志, 2020, 30(2): 90-97.
39. 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2021年版). 中国癌症杂志, 2021, 8(31): 770-856.
40. 郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析. 中华肿瘤杂志, 2019, 41(1): 19-28.
41. 曹毛毛, 陈万青. 中国恶性肿瘤流行情况及防控现状. 中国肿瘤临床, 2019, 46(3): 145-149.
42. Autier P, Boniol M, La Vecchia C, et al. Disparities in breast cancer mortality trends between 30 European countries: Retrospective trend analysis of WHO mortality database. BMJ, 2010, 341: c3620.
43. Michael G, Vinod R. Epidemiology, screening and diagnosis of breast cancer in the Asia–Pacific region: Current perspectives and important considerations. Asia-Pac J Clin Oncol, 2008, 4(s3): S5-S13.
44. Song QK, Li J, Huang R, et al. Age of diagnosis of breast cancer in China: Almost 10 years earlier than in the United States and the European Union. Asian Pac J Cancer Prev, 2014, 15(22): 10021-10025.
45. Yu ZG, Jia CX, Liu LY, et al. The prevalence and correlates of breast cancer among women in Eastern China. PLoS One, 2012, 7(6): e37784.
46. Mizukoshi MM, Hossian SZ, Poulos A. Comparative analysis of breast cancer incidence rates between australia and Japan: Screening target implications. Asian Pac J Cancer Prev, 2020, 21(7): 2123-2129.
47. Sechopoulos I, Mann RM. Stand-alone artificial intelligence - The future of breast cancer screening? Breast, 2020, 49: 254-260.
48. 瞿亚军, 吕青. 我国乳腺癌预防若干问题的思考. 中国普外基础与临床杂志, 2020, 27(11): 1334-1339.
49. 吕青, 瞿亚军. 乳腺良性疾病与乳腺癌风险. 中国普外基础与临床杂志, 2020, 27(11): 1329-1333.

Next Article
Insights into the clinical studies related to cardiovascular surgery from the American Heart Association’s Scientific Sessions 2021: Part one

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Interpretation of the global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020

Abstract Full text Figures/Tables Video References Cited by

Next Article

Format

Content